NasdaqCM - Delayed Quote USD

Regulus Therapeutics Inc. (RGLS)

2.4200

+0.1500

(+6.61%)

At close: April 26 at 4:00 PM EDT

Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements

Financial and Clinical Progress Amidst Net Loss Wider Than Estimates

GuruFocus.com last month

RGLS
+6.61%
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.

PR Newswire last month

RGLS
+6.61%
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More

Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.

Zacks last month

AMLX

MRNA

RGLS
+6.61%
Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study

Data from an early-stage study shows that treatment with Regulus' (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.

Zacks last month

RGLS
+6.61%
ADMA

ANIP
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has entered into a definitive securities purchase agreement in connection with a private placement to certain institutional investors and other accredited investors. The oversubscribed financing includes participation from new and existing institutional investors, including Adage Capital Pa

PR Newswire last month

RGLS
+6.61%
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced positive topline results from the second cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD.

PR Newswire last month

RGLS
+6.61%
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced it has completed enrollment in the third cohort of patients in the Phase 1b MAD study of RGLS8429 for the treatment of ADPKD.

PR Newswire 3 months ago

RGLS
+6.61%
Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that CEO Jay Hagan will be participating in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday November 29, at 10:25 a.m. ET.

PR Newswire 5 months ago

RGLS
+6.61%
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results and provided a corporate update for the third quarter ended September 30, 2023.

PR Newswire 5 months ago

RGLS
+6.61%
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the dosing of the first patient in the third cohort of the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD.

PR Newswire 5 months ago

RGLS
+6.61%
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced, after review of all available safety data, that it will advance to the third cohort of patients in the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. Patients in the third cohort will receive 3 mg/kg of RGLS8429 or placebo every other week for three months.

PR Newswire 6 months ago

RGLS
+6.61%
Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced positive topline results from the first cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD.

PR Newswire 7 months ago

RGLS
+6.61%
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced it has completed enrollment in the second cohort of patients in the ongoing Phase 1b MAD study of RGSL8429 for the treatment of ADPKD.

PR Newswire 7 months ago

RGLS
+6.61%
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will host investor meetings at the Wells Fargo Healthcare Conference, and present and host meetings at the H.C. Wainwright 25th Annual Global Investor Conference.

PR Newswire 7 months ago

RGLS
+6.61%
Regulus Therapeutics (RGLS): An Attractive Valuation or a Potential Value Trap?

Unveiling the Underlying Risks and Rewards of Investing in Regulus Therapeutics

GuruFocus.com 7 months ago

RGLS
+6.61%
Regulus Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance

An In-depth Analysis of Regulus Therapeutics Inc's GF Score

GuruFocus.com 7 months ago

RGLS
+6.61%
Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it will host a virtual investor event on Wednesday, September 6, 2023, focused on its lead program, RGLS8429, a novel therapy in clinical development for the treatment of autosomal dominant polycystic kidney disease (ADPKD).

PR Newswire 7 months ago

RGLS
+6.61%
Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results and provided a corporate update for the second quarter ended June 30, 2023.

PR Newswire 8 months ago

RGLS
+6.61%
Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that CEO Jay Hagan will be presenting at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023, at 11:30 a.m. ET.

PR Newswire 8 months ago

RGLS
+6.61%
Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Dr. Preston Klassen, President and Head of Research & Development of Regulus, will present at the H.C. Wainwright 2nd Annual Kidney Conference on Tuesday, July 25, 2023 at 3:00 p.m. ET.

PR Newswire 9 months ago

RGLS
+6.61%

Performance Overview

Return	RGLS	S&P 500
YTD	+89.06%	+6.92%
1-Year	+77.94%	+25.26%
3-Year	-83.08%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Regulus Therapeutics Inc. (RGLS)

Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements

Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates

Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More

Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study

Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity

Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference

Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates

Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

Regulus Therapeutics (RGLS): An Attractive Valuation or a Potential Value Trap?

Regulus Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance

Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023

Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates

Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference

Performance Overview